Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with Iodine-131 Anti-B1 Antibody in NHL
NCT00022893Phase 2Unknown
- Sponsor
- Corixa Corporation
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tositumomab in non-Hodgkin lymphoma (NHL), sponsored by Corixa Corporation. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
tositumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00022893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022893.